Get the Stockscreener App
16.98
9.76%
1.51
After Hours:
16.85
-0.13
-0.77%
Uniqure N V stock is traded at $16.98, with a volume of 2.04M.
It is up +9.76% in the last 24 hours and up +197.89% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$15.47
Open:
$15.58
24h Volume:
2.04M
Relative Volume:
1.04
Market Cap:
$827.66M
Revenue:
$15.84M
Net Income/Loss:
$-308.48M
P/E Ratio:
-4.3096
EPS:
-3.94
Net Cash Flow:
$-153.08M
1W Performance:
+10.26%
1M Performance:
+197.89%
6M Performance:
+272.37%
1Y Performance:
+172.33%
1-Day Range:
$15.35
$17.58
1-Week Range:
$14.68
$17.71
52-Week Range:
$3.73
$17.71
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
16.98 | 827.66M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
(QURE) Technical Pivots with Risk Controls - Stock Traders Daily
uniQure (NASDAQ:QURE) Trading Up 5.8% on Analyst Upgrade - MarketBeat
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug - MSN
uniQure (NASDAQ:QURE) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
CSL and uniQure Win 2023 Prix Galien USA Award - GuruFocus.com
57,333 Shares in uniQure (NASDAQ:QURE) Purchased by Y Intercept Hong Kong Ltd - MarketBeat
Around the Helix: Cell and Gene Therapy Company Updates – December 18, 2024 - CGTLive™
uniQure price target raised to $32 from $12 at Stifel - Yahoo Finance
uniQure (NASDAQ:QURE) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
uniQure (NASDAQ:QURE) Price Target Raised to $32.00 at Stifel Nicolaus - MarketBeat
uniQure (NASDAQ:QURE) Shares Acquired by Fmr LLC - MarketBeat
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025? - Yahoo Finance
uniQure (NASDAQ:QURE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
uniQure (NASDAQ:QURE) Trading 5.2% Higher Following Analyst Upgrade - MarketBeat
uniQure FY2024 EPS Estimate Reduced by Leerink Partnrs - MarketBeat
Biotech Alert: Searches spiking for these stocks today - TipRanks
Real-World Evidence Helps Open Accelerated Approval Pathway For Neurodegeneration Therapies - News & Insights
QURE (uniQure NV) Free Cash Flow : $-193.09 Mil (TTM As of Sep. 2024) - GuruFocus.com
Wells Fargo & Company Upgrades uniQure (NASDAQ:QURE) to "Strong-Buy" - MarketBeat
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More - MSN
Goldman maintains Neutral rating on uniQure shares, cites FDA review By Investing.com - Investing.com Nigeria
Goldman maintains Neutral rating on uniQure shares, cites FDA review - Investing.com
UniQure Stock Hits 52-Week High at $13.72 Amidst Modest Annual Growth - Investing.com Canada
uniQure (NASDAQ:QURE) Shares Sold by Verition Fund Management LLC - MarketBeat
Raymond James Upgrades uniQure N.V. (QURE) - MSN
uniQure (NASDAQ:QURE) Upgraded to Sell at StockNews.com - MarketBeat
UniQure Stock Hits 52-Week High at $13.72 Amidst Modest Annual Growth By Investing.com - Investing.com South Africa
UniQure: Accelerated Approval Plan With US FDA May Save Five Years - Citeline
uniQure CFO Christian Klemt sells $13,559 in stock By Investing.com - Investing.com Nigeria
Uniqure stock doubles as FDA points to a BLA in Huntington’s - BioWorld Online
uniQure CFO Christian Klemt sells $13,559 in stock - Investing.com
uniQure CEO Matthew Kapusta sells $26,079 in stock By Investing.com - Investing.com Nigeria
uniQure’s AMT-130: A Bold Step For Huntington’s, But Not Without Hurdles (NASDAQ:QURE) - Seeking Alpha
uniQure CEO Matthew Kapusta sells $26,079 in stock - Investing.com India
uniQure stock boosted by FDA alignment on accelerated approval for AMT-130 - Investing.com
UniQure doubles on alignment with FDA on development plan for gene therapy - XM
uniQure Soars 111% on FDA Approval - Wall Street Pit
Gene therapy developer's stock doubles after FDA grants accelerated approval - The Business Journals
Raymond James, Cantor bullish on uniQure following FDA update (NASDAQ:QURE) - Seeking Alpha
UniQure (QURE) Stock Soars Over 121% on FDA Approval Pathway - GuruFocus.com
uniQure soars as it aligns regulatory path for Huntington’s candidate AMT-130 - The Pharma Letter
uniQure stock rockets 90% on FDA update for AMT-130 (NASDAQ:QURE) - Seeking Alpha
UniQure Shares Double After FDA Agreement on Pathway for Huntington's Disease Treatment - Marketscreener.com
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday - Benzinga
uniQure shares surge on FDA accelerated approval pathway accord By Investing.com - Investing.com South Africa
uniQure aligns with FDA on Accelerated Approval for AMT-130 - Investing.com India
uniQure shares surge on FDA accelerated approval pathway accord - Investing.com India
uniQure aligns with FDA on Accelerated Approval for AMT-130 By Investing.com - Investing.com Canada
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease - The Manila Times
uniQure Announces Alignment with FDA on Key Elements of - GlobeNewswire
UniQure shares soar on chance of speedy approval for Huntington’s therapy - Yahoo Finance
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Uniqure N V Stock (QURE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director |
Dec 10 '24 |
Sale |
15.03 |
100,000 |
1,503,000 |
597,915 |
| Kapusta Matthew C | CEO, Managing Director |
Dec 09 '24 |
Sale |
7.63 |
3,418 |
26,079 |
597,915 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Dec 09 '24 |
Sale |
7.55 |
1,796 |
13,560 |
166,713 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):